Literature DB >> 11287594

AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies.

S Giannecchini1, D Del Mauro, D Matteucci, M Bendinelli.   

Abstract

In the feline immunodeficiency virus system, immunization with a fixed-infected-cell vaccine conferred protection against virulent homologous challenge but the immune effectors involved remained elusive. In particular, few or no neutralizing antibodies were detected in sera from vaccinated cats. Here we show that, when preadsorbed with selected feline cells, the same sera revealed clearly evident virus-neutralizing activity. Because high titers of neutralizing antibody in cell-adsorbed sera from 23 cats immunized with fixed-infected-cell or whole-inactivated-virus vaccines correlated with protection, it is likely that they were more important for protection than formerly realized. In vitro, the fixed-cell vaccine efficiently removed neutralizing antibody from immune sera while the whole-inactivated-virus vaccine was much less effective.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287594      PMCID: PMC114190          DOI: 10.1128/JVI.75.9.4424-4429.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  HIV/AIDS Vaccine Development: Challenges, Progress and Future Directions.

Authors: 
Journal:  Rev Med Virol       Date:  1996-09       Impact factor: 6.989

2.  Immune correlates of protection from HIV and AIDS - more answers but yet more questions.

Authors:  J L Heeney; P Beverley; A McMichael; G Shearer; J Strominger; B Wahren; J Weber; F Gotch
Journal:  Immunol Today       Date:  1999-06

3.  HIV-1 neutralizing antibodies: how full is the bottle?

Authors:  J P Moore; D R Burton
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

4.  Roundtable: can experience with veterinary retroviral vaccines be applied to the human situation?

Authors: 
Journal:  AIDS Res Hum Retroviruses       Date:  1996-03-20       Impact factor: 2.205

Review 5.  FIV infection of the domestic cat: an animal model for AIDS.

Authors:  B J Willett; J N Flynn; M J Hosie
Journal:  Immunol Today       Date:  1997-04

6.  Vaccination with fixed feline immunodeficiency virus (FIV) infected cells: protection, breakthrough and specificity of response.

Authors:  S A Bishop; C R Stokes; T J Gruffydd-Jones; C V Whiting; J E Humphries; R Osborne; M Papanastasopoulou; D A Harbour
Journal:  Vaccine       Date:  1996-09       Impact factor: 3.641

7.  Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses.

Authors:  G Gilljam
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

8.  The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity.

Authors:  A Trkola; C Gordon; J Matthews; E Maxwell; T Ketas; L Czaplewski; A E Proudfoot; J P Moore
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

9.  Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system.

Authors:  F Baldinotti; D Matteucci; P Mazzetti; C Giannelli; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  Antibodies to human and non-human primate cellular and culture medium components in macaques vaccinated with the simian immunodeficiency virus.

Authors:  L A Bergmeier; J Walker; L Tao; M Cranage; T Lehner
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

View more
  6 in total

1.  Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.

Authors:  Margaret J Hosie; Dieter Klein; James M Binley; Thomas H Dunsford; Oswald Jarrett; James C Neil; Elzbieta Knapp; Simone Giannecchini; Donatella Matteucci; Mauro Bendinelli; James A Hoxie; Brian J Willett
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

2.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Authors:  Simone Giannecchini; Patrizia Isola; Olimpia Sichi; Donatella Matteucci; Mauro Pistello; Lucia Zaccaro; Daniela Del Mauro; Mauro Bendinelli
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

3.  A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

Authors:  Emma T Crooks; Penny L Moore; Michael Franti; Charmagne S Cayanan; Ping Zhu; Pengfei Jiang; Robbert P de Vries; Cheryl Wiley; Irina Zharkikh; Norbert Schülke; Kenneth H Roux; David C Montefiori; Dennis R Burton; James M Binley
Journal:  Virology       Date:  2007-06-19       Impact factor: 3.616

4.  Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus.

Authors:  Simone Giannecchini; Mauro Pistello; Patrizia Isola; Donatella Matteucci; Paola Mazzetti; Giulia Freer; Mauro Bendinelli
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

Review 5.  Feline immunodeficiency virus (FIV) neutralization: a review.

Authors:  Margaret J Hosie; Daniela Pajek; Ayman Samman; Brian J Willett
Journal:  Viruses       Date:  2011-10-13       Impact factor: 5.048

Review 6.  FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review.

Authors:  E W Uhl; T G Heaton-Jones; R Pu; J K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2002-12       Impact factor: 2.046

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.